Alumis New Phase 3 ONWARD Data Show Envudeucitinib Improved Scalp, Itch And Quality Of Life In Psoriasis, Building On 54% PASI 100 At Week 48; NDA On Track For 4Q 2026
– Results build on ONWARD3 highest complete skin clearance (54% PASI 100) at Week 48, reinforcing envudeucitinib’s potential to become a leading oral therapy for moderate-to-severe plaque psoriasis– Patients switching